Penumbra, Inc. (NYSE:PEN) Q3 2019 Earnings Conference Call - Final Transcript

Nov 07, 2019 • 04:30 pm ET

Previous

Penumbra, Inc. (NYSE:PEN) Q3 2019 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Operator
Operator

[Operator Instructions] Your first question will come from the line of Larry Biegelsen of Wells Fargo. Please go ahead, your line is open.

Analyst
Larry Biegelsen

Hey, good afternoon, guys. Thanks for taking the question. Two for me, One on the REAL system and one on stroke Adam, So first on the REAL system. What's the latest there? Where are you in your preparations for commercialization? And how meaningful can revenues be in 2020 even just directionally would be helpful? And I have one follow-up.

Executive
Adam Elsesser

Okay, great question. So we're going to go into as we have said in the past a little more involved detail at the Investor Day coming up in December. We are prepared and getting ready for a launch in 2020 of that system. So that time frame is on track as we have indicated in the past. And we'll use the opportunity at the Investor Day to sort of go through the details of the commercial launch or the pricing the model itself as well as give you some early indication of what we think the expectations will be for that product in 2020.

Analyst
Larry Biegelsen

Fair enough. And then Adam this year you've been talking about changing the stroke treatment paradigm. So I guess my question is where are you on that path? Are you still on track to accomplish that over the next 12 to 18 months? And when are we going to learn more about this lightning system? Are we going to learn more at the Investor Day?

Executive
Adam Elsesser

Great question. Let me try to answer that question the right way. The answer to the first sort of larger question of how far along are we are we still on track around my comments about continuing to sort of change the paradigm which as I've said publicly really involves getting all of the clot out in -- as fast the time frame as possible for almost all the patients. The answer is we are still very much on track with that work and there's no update on specific timing but there are certainly not -- there has not been a delay or change in my optimism around that. I still am very excited to continue to provide a lot of the innovation that this field has seen and enjoyed over the last sort of four or five years and I remain excited about that. As it relates to the product name lightning which I think you determined as part of a trademark filing I think it's premature to attribute that product name to any particular franchise within our business. And we'll just have to wait till that product is cleared or approved and launched.

Analyst
Larry Biegelsen

Alright guys, thanks for taking the question.

Operator
Operator

Your next question will come from the line of Jason Mills of Canaccord. Please go ahead, your lines open

Analyst
Jason Mills

I'm sorry I was on mute. Adam can you hear me okay?

Executive
Adam Elsesser

Yes I can Jason.

Analyst
Jason Mills

Congratulation on a great quarter. I wanted to start outside of the U.S.